HROW (Harrow, Inc.) חוב לטווח קצר להון

Harrow, Inc. (HROW) is aggressively expanding its patient reach, leveraged by FDA support and physician loyalty within its network. Inelastic demand for ophthalmological products guarantees the company a steady cash flow, which currently stands at 0.00. The market trend of the asset shown on this price chart complements the analysis of a business that generates revenue from the sale of branded dry eye treatments through its own capacities.

The specifics of manufacturing sterile ophthalmic products within a protected US niche require stable funding, which is reflected in the ratio of current liabilities under one year to equity for Harrow, Inc. (HROW). This indicator compares short-term loans with equity, allowing investors to assess default risk: an increase in the metric signals dangerous over-leverage, while its decline confirms the business's resilience to market turbulence.